Comparative Pharmacology
Head-to-head clinical analysis: PREVACID 24 HR versus RABEPRAZOLE SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PREVACID 24 HR versus RABEPRAZOLE SODIUM.
PREVACID 24 HR vs RABEPRAZOLE SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Proton pump inhibitor (PPI) that irreversibly inhibits the H+/K+-ATPase enzyme system (proton pump) at the secretory surface of gastric parietal cells, suppressing basal and stimulated gastric acid secretion.
Rabeprazole is a proton pump inhibitor (PPI) that inhibits the gastric H+/K+-ATPase enzyme at the secretory surface of gastric parietal cells, thereby suppressing basal and stimulated gastric acid secretion. It is a substituted benzimidazole that accumulates in the acidic environment of the parietal cell and is protonated, forming a covalent disulfide bond with cysteine residues of the proton pump, leading to irreversible inhibition.
15 mg orally once daily for 14 days.
Oral: 20 mg once daily; duodenal ulcer: 20 mg once daily for up to 4 weeks; erosive esophagitis: 20 mg once daily for 4 to 8 weeks; GERD: 20 mg once daily for 4 to 8 weeks; Helicobacter pylori eradication: 20 mg twice daily in combination with antibiotics.
None Documented
None Documented
1.2-1.5 hours in healthy subjects; no accumulation with once-daily dosing.
1-2 hours in most individuals, but pharmacodynamic half-life is longer (24-48 hours) due to irreversible binding to proton pumps; clearance is reduced in hepatic impairment (half-life up to 12 hours)
Approximately 66% renal (as metabolites), 33% fecal (primarily biliary); less than 1% unchanged in urine.
Primarily renal (approx. 90% as metabolites, <1% unchanged) and fecal (approx. 10%)
Category C
Category A/B
Proton Pump Inhibitor
Proton Pump Inhibitor